Cambridge, Massachusetts, July 10, 2018-Vedanta Biosciences, an affiliate of PureTech Health (LSE: PRTC) developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced […]
UAS Labs (Wausau, Wisconsin, USA) is excited to announce their licensing agreement with AceBiome (Gyeonggi-do, South Korea), a recent spin-off of the parent biotechnology company Bioneer (Daejeon, South Korea). This agreement includes the manufacturing and […]
Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.’s high-throughput bacteriophage (“phage”) discovery platform. Pairing EpiBiome’s powerful phage isolation and characterization capability with Locus’s CRISPR-based […]
Eurofins Will Use DuPont Assays to Identify Probiotics at the Strain Level. DuPont Nutrition & Health and Eurofins have developed and validated strain-level identification assays in probiotic testing, leading the way for industrywide product integrity […]
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, announced that the Phase 3 study with Oxabact® in Primary Hyperoxaluria (PH) is now fully open for recruitment. All clinics participating in the study are approved by Competent authorities […]
Diversigen Inc. (Houston, TX) and Norgen Biotek Corp. (Ontario, Canada) announced that they have entered into a strategic partnership through which industry and academic researchers will benefit from comprehensive end-to-end logistical, sequencing, and analytical solutions […]
Morinaga Milk Industry Co., Ltd., (TOKYO:2264) today announced it has attained self-affirmed GRAS (generally recognized as safe) status in the United States for LAC-Shield, a unique immunogenic ingredient. This development opens the door for manufacturers of […]
Jennewein Biotechnologie announces that on June 15, 2018, it signed a long-term lease for a 1000-m2 plot of land on Mildred-Scheel-Straße, Bonn Bad Godesberg, which will be the site of a new R&D centre for […]
Paris (France), July 5, 2018 – Nextbiotix, a microbiome biotech company developing innovative Live Biotherapeutics using commensal bacteria as drugs to treat major inflammatory bowel diseases, today announced that it has completed a €7m Series […]
On April 6, 2018, BioGaia became the majority shareholder in MetaboGen with a 62 percent stake. BioGaia has now, after the set milestones have been achieved, decided to further extend its holding, resulting in a […]